$AMTX

Aemetis (AMTX) Stock Pops As Operating Profit Returns But Cash Risk Lingers

Simply Wall St reports Aemetis (AMTX) shares rose 5.5% to $1.72 after its Q2 release. Q2 revenue rose to $62.7m from $52.2m. The company swung to operating income of $5.8m from an operating loss, while net loss narrowed to $9.4m. The article cites $1m cash and ongoing liquidity and policy execution risks.

Original reporting
Published Aug 8, 2026, 9:46 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aemetis (AMTX) Stock Pops As Operating Profit Returns But Cash Risk Lingers — source image
Decision brief

The 30-second read

$AMTXNeutralMed
01

Why it matters

Traders may reprice the probability of an earnings reset due to positive operating income, while simultaneously discounting the durability of that improvement given very low cash and ongoing policy and project-timing dependencies.

02

Market read

Q2 results create a near-term catalyst for AMTX, but the liquidity and execution/policy risks described may keep volatility elevated.

03

What to watch

The article notes multiple digesters awaiting CARB approval and reliance on DOE emissions-calculator updates for 45Z values, which could delay or reduce credit economics.

Relevance 6/10Novelty 6/10Timing: post-Q2 release, pre-market/early trading today

Background

Simply Wall St summarizes Aemetis Q2 2026 performance, emphasizing a margin turnaround alongside continued net losses and balance-sheet strain.

Company-level read

Ticker impact

$AMTXNeutralMedium confidence
Context

Aemetis shares jumped 5.5% after Q2 results showed revenue of $62.7m, operating income of $5.8m, and a narrowed net loss to $9.4m.

Expected impact

Likely choppy post-earnings action, with upside capped unless cash burn and policy/execution milestones improve.

Evidence & confidence

The disclosed datapoints are directionally positive on operating income and revenue growth, but the same release narrative emphasizes cash scarcity, interest/overhead drag, and execution timing into end-2026.

Market effects

Highlights how LCFS pathway approvals and 45Z credit economics can swing RNG/low-carbon fuel margins, but also underscores execution and liquidity sensitivity.

No clear regional spillover beyond US low-carbon fuel policy-linked names.

Limited, as the catalysts described are US regulatory and tax-credit specific.

Counterpoint

The operating-profit swing may be credit- and timing-dependent, so the stock pop could fade if cash burn and overheads remain unchanged.

Key entities

  • Aemetis

    Low-carbon fuel and RNG producer whose Q2 results show operating income improvement but persistent net loss and liquidity strain.

  • CARB

    California Air Resources Board, whose pathway approvals are cited as validating higher-value dairy RNG pathways.

  • Section 45Z

    US tax credit referenced as a key driver of credit economics, including a July credit sale.

  • DOE emissions calculator

    Referenced as a factor that could change 45Z values once updated.

Related articles

$AMTXMedAI 8/10

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) reported Q2 2026 revenue of $62.7M, up 20% YoY, with operating income of $5.8M, reversing a prior-year loss. Growth was driven by ethanol and renewable natural gas segments. Adjusted EBITDA improved to $9.7M from -$5.8M. Management highlighted projects like mechanical vapor recompression and LCFS pathway approvals, but noted risks from uncertain emissions rates and feedstock constraints.

$AMTXMed

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) Q2 2026 earnings call said consolidated revenue rose 20% year over year, operating income improved by $16.4 million, and adjusted EBITDA increased by $15.5 million versus Q2 2025. The company cited CARB approval of 7 LCFS pathways and pending approvals for 6 digesters, plus ethanol projects including a $32 million annual cash flow MVR system. India biodiesel revenue was $2.5 million, with expected $17 million from new allocations.

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

$AMTXMed

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com Aemetis Reports Second Quarter 2026 Financial Results Revenue Growth o

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.